Lawrence Berk - Concepedia

Author

Lawrence Berk

University of South Florida ORCID

Also Known As

Berk, Lawrence, DeNittis, Albert, L B Berk, L BERK, L Berk, L. B. Berk, L. Berk, L.B Berk, L.B. Berk, LB Berk

111

Publications

4.1K

Citations

H-Index

Concepts

All Affiliations

University of South Florida Moffitt Cancer Center RTOG Foundation The University of Texas MD Anderson Cancer Center Juravinski Cancer Centre

About

Lawrence Berk is an author at University of South Florida specializing in medicine, radiation oncology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	22	2.2K
2	Health Sciences	7	7	600
3	Classical Hematology	1	1	27
4	Immunology	1	1	14
5	Medical Laboratory Science	1	1	27

Lawrence Berk

Publications

2.7K

Citations

H-Index

Page 1

	Year	Citations
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial Michael Weller, Nicholas Butowski, David Tran, The Lancet Oncology Egfrviii-expressing GlioblastomaNeuro-oncologyAct IvGliomaInternational Phase 3	2017	1.1K
RTOG 0631 phase 2/3 study of image guided stereotactic radiosurgery for localized (1-3) spine metastases: Phase 2 results Samuel Ryu, Stephanie L. Pugh, Peter C. Gerszten, Practical Radiation Oncology Adaptive RadiotherapyNeuro-oncologySurgical OncologyMedical ImagingRadiation Therapy	2013	262
Single‐fraction radiotherapy versus multifraction radiotherapy for palliation of painful vertebral bone metastases—Equivalent efficacy, less toxicity, more convenient David D. Howell, J. James, William F. Hartsell, Cancer	2012	149
A randomized, double-blind, placebo-controlled trial of a β-hydroxyl β-methyl butyrate, glutamine, and arginine mixture for the treatment of cancer cachexia (RTOG 0122) Lawrence Berk, J. James, Anna L. Schwartz, Supportive Care in Cancer OncologyCancer CachexiaRtog 0122Chemoprevention StrategyPharmacology	2008	115
Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial Ethan Basch, Stephanie L. Pugh, Amylou C. Dueck, International Journal of Radiation OncologyBiologyPhysics Adverse EventsOncologyAdverse EventClinical EndpointPatient Safety	2017	115
Phase III Trial of an Emulsion Containing Trolamine for the Prevention of Radiation Dermatitis in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck: Results of Radiation Therapy Oncology Group Trial 99-13 Elizabeth Elliott, James R. Wright, Ruth Swann, Journal of Clinical Oncology	2006	113
A Phase II Study of Intensity Modulated Radiation Therapy to the Pelvis for Postoperative Patients With Endometrial Carcinoma: Radiation Therapy Oncology Group Trial 0418 Anuja Jhingran, Kathryn Winter, Lorraine Portelance, International Journal of Radiation OncologyBiologyPhysics Radiation TherapyPostoperative PatientsMedicineGynecologyPhase Ii Study	2012	96
RTOG 0631 Phase II/III Study of Image-guided Stereotactic Radiosurgery for Localized Spine Metastases: Phase II Results Seung Ryu, J. James, Peter C. Gerszten, International Journal of Radiation OncologyBiologyPhysics Phase Ii ResultsNeuro-oncologySurgical OncologyMedical ImagingRadiation Therapy	2011	72
An overview of radiotherapy trials for the treatment of brain metastases. Lawrence Berk PubMed Adaptive RadiotherapyNeuro-oncologyRadiotherapy TrialsPrognostic FactorsEnglish Literature	1995	62
Modeling the effect of intratumoral heterogeneity of radiosensitivity on tumor response over the course of fractionated radiation therapy Juan Carlos López Alfonso, Lawrence Berk Radiation Oncology	2019	62

Page 1